Prognostic Value of Purified Protein Derivative Skin Test and Granuloma Formation in Patients Treated with Intravesical Bacillus Calmette-Guerin-Reference-Cited by-同舟云学术

Prognostic Value of Purified Protein Derivative Skin Test and Granuloma Formation in Patients Treated with Intravesical Bacillus Calmette-Guerin

Published:1986-02 Issue:2 Volume:135 Page:268-271
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kelley David R.¹,Haaff Eric O.¹,Becich Michael¹,Lage Janice¹,Bauer Walter C.¹,Dresner Steven M.¹,Catalona William J.¹,Ratliff Timothy L.¹

Affiliation:

1. From the Division of Urology and Department of Pathology, The Washington University School of Medicine and The Jewish Hospital, St. Louis, Missouri

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference17 articles.

1. Treatment of superficial bladder cancer with intravesical BCG;Camacho;Proc. Amer. Ass. Cancer Res. Amer. Soc. Clin. Oncol.,1980

2. Bladder cancer immunotherapy;Lamm;J. Urol.,1982

3. Experience with bacillus Calmette-Guerin in patients with superficial bladder cancer;Brosman;J. Urol.,1982

4. BCG vs adriamycin in the treatment of transitional cell carcinoma in situ: a Southwest Oncology Group study;Lamm;J. Urol.,1985

5. The Japanese Urological Cancer Research Group for Adriamycin: Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer;Niijima;Cancer Chemother. Pharm.,1983

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral tuberculin purified protein derivative specific T cell immunoreactivity dynamics in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin instillation treatment;Frontiers in Oncology;2022-10-27

2. BCG Immunotherapy: Old Tool and New Concepts;Handbook of Cancer and Immunology;2022

3. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches;The Journal of Pathology;2019-06-24

4. Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial;OncoImmunology;2019-05-25

5. Mechanisms of BCG immunotherapy and its outlook for bladder cancer;Nature Reviews Urology;2018-07-10